Skip to main content
Terug
Watch Compare

Silence Therapeutics plc

Datakwaliteit: 100%
Ook genoteerd als SLNCF Nasdaq
SLN
Nasdaq Manufacturing Chemicals
€ 5,66
▼ € 0,19 (-3,25%)
Marktkapitalisatie: 267,34 M
Prijs
€ 5,66
Marktkapitalisatie
267,34 M
Dagbereik
€ 5,57 — € 5,77
52-Weeksbereik
€ 1,97 — € 7,91
Volume
149.614
Openen € 5,76
50D / 200D Gem.
€ 5,46
3,62% above
50D / 200D Gem.
€ 5,82
2,80% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -62,33 M
Capital efficient — spends only 9,84% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-98,71%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-105,35%
Onder sectorgemiddelde (-53,41%)
ROIC-51,42%
Net Margin-15851,88%
Op. Margin-16292,84%

Veiligheid

Debt / Equity
N/A
Current Ratio7,69
Interest CoverageN/A

Waardering

PE (TTM)
-3,02
Onder sectorgemiddelde (-1,48)
P/B Ratio3,61
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -3,0 -1,5
P/B 3,6 1,6
ROE % -105,4 -53,4
Net Margin % -15851,9 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
0,89% weight
SNTKX SNTKX
0,01% weight
SNTCX SNTCX
0,01% weight
SNTFX SNTFX
0,01% weight
SNTDX SNTDX
0,01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -98,71% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 559.000,0 Net Income (TTM) -88,61 M
ROE -105,35% ROA -56,80%
Gross Margin 61,54% Operating Margin -16292,84%
Net Margin -15851,88% Free Cash Flow (TTM) -62,33 M
ROIC -51,42% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 7,69
Interest Coverage N/A Asset Turnover 0,00
Working Capital 116,25 M Tangible Book Value 63,45 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,02 Forward P/E N/A
P/B Ratio 3,61 P/S Ratio 478,25
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -23,31%
Market Cap 267,34 M Enterprise Value 185,31 M
Per Share
EPS (Diluted TTM) -0,63 Revenue / Share 0,01
FCF / Share -1,32 OCF / Share -1,32
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 9,84% FCF Conversion 70,34%
SBC-Adj. FCF -70,40 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue 559.000,0 43,26 M
Net Income -88,61 M -45,31 M
EPS (Diluted) -0,63 -0,33
Gross Profit 344.000,0 31,45 M
Operating Income -91,08 M -63,32 M
EBITDA — —
R&D Expenses 67,75 M 67,88 M
SG&A Expenses — —
D&A — —
Interest Expense — —
Income Tax 11.000,0 845.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 131,44 M 202,64 M
Total Liabilities 69,14 M 68,61 M
Shareholders' Equity 62,30 M 134,02 M
Total Debt — —
Cash & Equivalents 11,28 M 121,33 M
Current Assets 118,66 M 187,37 M
Current Liabilities 13,61 M 16,82 M